Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Return of Vocal Fold Motion and Surgical Preservation of Invaded Recurrent Laryngeal Nerves After the Use of Neoadjuvant Therapy in Patients Presenting with Advanced Thyroid Cancer and Vocal Fold Paralysis: The Lazarus Effect.
Silver Karcioglu A, Abdelhamid Ahmed AH, Feng Z, Russell M, Shonka DC Jr, Iwata A, Cabanillas M, Shin JJ, Kyriazidis N, Park JC, Wirth LJ, Zafereo ME, Randolph GW. Silver Karcioglu A, et al. Among authors: wirth lj. Thyroid. 2023 Oct;33(10):1259-1263. doi: 10.1089/thy.2023.0136. Thyroid. 2023. PMID: 37694677 No abstract available.
A phase II study of gefitinib in patients with advanced thyroid cancer.
Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. Pennell NA, et al. Among authors: wirth lj. Thyroid. 2008 Mar;18(3):317-23. doi: 10.1089/thy.2007.0120. Thyroid. 2008. PMID: 17985985 Clinical Trial.
ROS1 Rearrangement in Thyroid Cancer.
Ritterhouse LL, Wirth LJ, Randolph GW, Sadow PM, Ross DS, Liddy W, Lennerz JK. Ritterhouse LL, et al. Among authors: wirth lj. Thyroid. 2016 Jun;26(6):794-7. doi: 10.1089/thy.2016.0101. Thyroid. 2016. PMID: 27089969
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Brose MS, et al. Among authors: wirth lj. Lancet Oncol. 2016 Sep;17(9):1272-82. doi: 10.1016/S1470-2045(16)30166-8. Epub 2016 Jul 23. Lancet Oncol. 2016. PMID: 27460442 Free PMC article. Clinical Trial.
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabanillas ME, et al. Among authors: wirth lj. J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17. J Clin Oncol. 2017. PMID: 28817373 Free PMC article. Clinical Trial.
Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Hanna GJ, et al. Among authors: wirth lj. Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4. Clin Cancer Res. 2018. PMID: 29301825 Clinical Trial.
Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples.
Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG. Angell TE, et al. Among authors: wirth lj. Front Endocrinol (Lausanne). 2019 Sep 11;10:612. doi: 10.3389/fendo.2019.00612. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31572297 Free PMC article.
152 results